Expression of the human IGF-1 in transgenic plastids

Patent metadata

Field	Value
Publication number	US-9605045-B2
Application number	US-201414553647-A
Country	US
Kind code	B2
Filing date	Nov 25, 2014
Priority date	Jul 3, 2002
Publication date	Mar 28, 2017
Grant date	Mar 28, 2017

Abstract

A plastid transformation vector for stably transforming a plastid genome, comprising, as operably-linked components, a first flanking sequence, a DNA sequence coding for synthetic insulin-like growth factor-1 (IGF-1s) (SEQ ID NO. 1) or a substantially homologous DNA sequence of IGF-1s, which is capable of expression in the plastid genome, and a second flanking sequence.

First claim

What is claimed is:

1. A vector for transforming a plastid genome, said vector comprising, as operably-linked sequences, a trnI flanking sequence, a promoter operative in a plastid genome operably linked to a 5′ untranslated region (UTR) sequence, a DNA sequence comprising SEQ ID NO:2, which encodes insulin-like growth factor-1 (IGF-1), a 3′ untranslated region (UTR) sequence, and a trnA flanking sequence, wherein said vector comprises an expression cassette encoding an antibiotic-free selectable marker also located between the flanking sequences.

2. The vector of claim 1 , wherein said 5′ and 3′ UTRs comprise psbA 5′ and psbA 3′ sequence elements.

3. A vector for transforming a plastid genome, said vector comprising, as operably-linked sequences, a trnI flanking sequence, a promoter operative in a plastid genome operably linked to a 5′ untranslated region (UTR) sequence, a DNA sequence comprising SEQ ID NO:2, which encodes insulin-like growth factor-1 (IGF-1) for expression in said plastid genome, a 3′ untranslated region (UTR) sequence, and a trnA flanking sequence, wherein said vector comprises an expression cassette encoding Betaine aldehyde dehydrogenase (BADH) also located between the flanking sequences.

4. A method for producing IGF-1, said method comprising: integrating the vector of claim 1 into a plastid genome of a plant cell; and growing said plant cell to thereby express the IGF 1.

5. A recombinant plant, progeny or seed transformed with the transformation vector of claim 1 .

6. The plant of claim 5 , wherein said plant is an edible plant suitable for mammal consumption.

7. A plant containing at least one chloroplast transformed with the vector of claim 1 .

8. A recombinant plant, progeny or seed transformed with the transformation vector of claim 3 .

9. The plant of claim 8 , wherein said plant is an edible plant suitable for mammal consumption.

Assignees

• Univ Pennsylvania

Inventors

• Daniell Henry

Classifications

• C07K14/65 Primary

  Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N15/8257

  for the production of primary gene products, e.g. pharmaceutical products, interferon · CPC title

• C12N15/8214

  Plastid transformation · CPC title